Rheumatoid arthritis
Conditions
Brief summary
Proportion of participants achieving at least 20% improvement from baseline in the American College of Rheumatology (ACR) score at week 12
Detailed description
Change from baseline in Disease activity score – C-reactive protein (DAS-28 CRP) at week 12, Proportion of participants achieving at least 50% improvement from baseline in the ACR score at week 12, Number of participants with Treatment-Emergent Adverse Events (TEAEs), serious AEs (SAEs), and AEs of special interest (AESIs), Plasma pre-dose concentrations of SAR441566, Plasma post-dose concentrations of SAR441566
Interventions
Sponsors
Sanofi-Aventis Recherche & Developpement
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of participants achieving at least 20% improvement from baseline in the American College of Rheumatology (ACR) score at week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in Disease activity score – C-reactive protein (DAS-28 CRP) at week 12, Proportion of participants achieving at least 50% improvement from baseline in the ACR score at week 12, Number of participants with Treatment-Emergent Adverse Events (TEAEs), serious AEs (SAEs), and AEs of special interest (AESIs), Plasma pre-dose concentrations of SAR441566, Plasma post-dose concentrations of SAR441566 | — |
Countries
Czechia, Germany, Greece, Poland, Slovakia, Spain
Outcome results
None listed